Form D · Biotechnology
Argonaute RNA Ltd
Cardiff, X0 · CIK 0002157150
Offering snapshot reported Sep 24, 2026 · SEC filing
- Reported sold
- $1.8M Offering amount: $1.8M
- Investors reported
- 27 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Sep 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 24, 2026 | Initial | $1,800,000 | No comparison | 27 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598742
Source: Form D, filed Sep 24, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nabil Hussain Muhiddin Al Chalaby | Director |
| David William Dawson Ball | Director |
| Ross Thomas Burn | Director |
| Nigel Keith Davis | Director |
| Alexander Michael Fink | Director |
| Michael Mohamed Tarik Khan | Director, Executive |
| Johnathan Vincent Matlock | Director |
| Anthony Michael Parker | Director, Executive |
| Richard Michael Tompkins | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Cardiff Business Technology Centre Senghennydd Road
Cardiff, X0, CF24 4AY
Phone: 00441179742562
Cardiff, X0, CF24 4AY
Phone: 00441179742562